EFNS guideline on diagnosis and management of limb girdle muscular dystrophies

The limb girdle muscular dystrophies (LGMD) are termed as such as they share the characteristic feature of muscle weakness predominantly affecting the shoulder and pelvic girdles; their classification has been completely revised in recent years because of elucidation of many of the underlying genetic and protein alterations in the various subtypes. An array of diagnostic measures is possible but with varying ease of use and availability. Several aspects of muscle cell function appear to be involved in the causation of muscle pathology. These cellular variations may confer some specific clinical features thus permitting recognition of the LGMD subtype and hence directing appropriate levels of monitoring and intervention. Despite an extensive literature on the individual limb girdle dystrophies, these publications may be impenetrable for the general neurologist in this increasingly complex field. The proposed guidelines suggest an approach to the diagnosis and monitoring of the limb girdle dystrophies in a manner accessible to general neurologists.

[1]  C. Angelini,et al.  Molecular diagnosis in LGMD2A: Mutation analysis or protein testing? , 2004, Human mutation.

[2]  I. Richard,et al.  Titinopathies and extension of the M-line mutation phenotype beyond distal myopathy and LGMD2J , 2005, Neurology.

[3]  C. Angelini,et al.  Calpain-3 and dysferlin protein screening in patients with limb–girdle dystrophy and myopathy , 2001, Neurology.

[4]  C. Greenberg,et al.  Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. , 2002, American journal of human genetics.

[5]  Hanns Lochmüller,et al.  Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study , 2000, Neurology.

[6]  M. Brainin,et al.  Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004 * , 2004, European journal of neurology.

[7]  K. Bushby,et al.  Limb‐girdle muscular dystrophies – from genetics to molecular pathology , 2004, Neuropathology and applied neurobiology.

[8]  Susan C. Brown,et al.  Abnormalities in α-Dystroglycan Expression in MDC1C and LGMD2I Muscular Dystrophies , 2004 .

[9]  E. Hoffman,et al.  Homozygous α‐sarcoglycan mutation in two siblings: One asymptomatic and one steroid‐responsive mild limb–girdle muscular dystrophy patient , 1998, Muscle & nerve.

[10]  L. Anderson,et al.  Multiplex Western blotting system for the analysis of muscular dystrophy proteins. , 1999, The American journal of pathology.

[11]  S. Woodman,et al.  Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. , 2004, Neurology.

[12]  J. Bourke,et al.  107th ENMC International Workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th–9th June 2002, Naarden, the Netherlands , 2003, Neuromuscular Disorders.

[13]  C. Angelini,et al.  Extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2A phenotypes , 2005, Journal of Medical Genetics.

[14]  K. Campbell,et al.  Primary adhalinopathy (alpha-sarcoglycanopathy): clinical, pathologic, and genetic correlation in 20 patients with autosomal recessive muscular dystrophy. , 1997, Neurology.

[15]  M. Eagle.  Report on the Muscular Dystrophy Campaign workshop: Exercise in neuromuscular diseases Newcastle, January 2002 , 2002, Neuromuscular Disorders.

[16]  K. Bushby,et al.  The phenotype of calpainopathy: diagnosis based on a multidisciplinary approach , 2001, Neuromuscular Disorders.

[17]  I. Illa,et al.  A novel, blood‐based diagnostic assay for limb girdle muscular dystrophy 2B and miyoshi myopathy , 2002, Annals of neurology.

[18]  Francesco Muntoni,et al.  Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures , 2005, Neuromuscular Disorders.

[19]  H. Crijns,et al.  Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? , 2004, Journal of Molecular Medicine.

[20]  S. Pandya,et al.  Practice Parameter: Corticosteroid treatment of Duchenne dystrophy , 2005, Neurology.

[21]  J. Emparanza,et al.  LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. , 2005, Brain : a journal of neurology.

[22]  J. Bourke,et al.  The phenotype of limb-girdle muscular dystrophy type 2I , 2003, Neurology.

[23]  J. Beckmann,et al.  The 105th ENMC sponsored workshop: pathogenesis in the non-sarcoglycan limb-girdle muscular dystrophies, Naarden, April 12–14, 2002 , 2003, Neuromuscular Disorders.

[24]  F. J. Nattrass,et al.  On the classification, natural history and treatment of the myopathies. , 1954, Brain : a journal of neurology.

[25]  K. Bushby,et al.  Making sense of the limb-girdle muscular dystrophies. , 1999, Brain : a journal of neurology.

[26]  J. Beckmann,et al.  66th/67th ENMC Sponsored International Workshop: The Limb-Girdle Muscular Dystrophies 26–28 March 1999, Naarden, The Netherlands , 1999, Neuromuscular Disorders.

[27]  A. Pestronk,et al.  Primary α‐sarcoglycan deficiency responsive to immunosuppression over three years , 1998 .